- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04517435
ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma
An Open-Label, Phase I/II Study of ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a multi-institution, open-label, phase I/II study designed to evaluate the safety and efficacy of R-CHOP + ME-401 for participants with newly diagnosed DLBCL.
Objectives for the phase I portion of this study are as follows:
Primary objectives:
- To determine the recommended phase 2 dose (RP2D) of ME-401in combination with R-CHOP for participants with newly diagnosed DLBCL.
- To describe tolerability of ME-401 in combination with R-CHOP for participants with newly diagnosed DLBCL.
Objectives for the phase II portion of this study are as follows:
- To estimate the clinical activity of ME-401 in combination with R-CHOP in participants with newly diagnosed DLBCL, as measured by 1 year PFS rate
- To estimate the response rates (complete and partial remission),duration of response (DOR), time to progression (TTP), and overall survival (OS) with ME-401 plus R-CHOP.
- To characterize treatment-related AEs in participants treated with ME-401 plus R-CHOP.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Deepa Jagadeesh, MD, MPH
- Phone Number: 1-866-223-8100
- Email: TaussigResearch@ccf.org
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Participants must have histologically confirmed diffuse large B-cell lymphoma (DLBCL). Participants with previously diagnosed indolent lymphoma (follicular and marginal zone lymphoma but not small lymphocytic lymphoma) who have transformed to DLBCL are eligible only if they have not previously been treated for indolent lymphoma.
--If participants received single rituximab (maximum 4-8 doses with no maintenance) for their low grade lymphoma ≥12 months prior to starting study drug are eligible to participate
- Participants must have radiographically measurable disease. At least one bi-dimensionally measurable nodal lesion ≥1.5 cm in its longest diameter by CT scan or MRI, as defined by the Lugano Classification
- Patients participating in the phase II part are allowed to receive brief (<15 days) treatment with glucocorticoids (max dose of prednisone 40 mg) and/or 1 cycle of chemotherapy such as R-CHOP [or some component(s) thereof] for the diagnosis of B-cell lymphoma provided they had all necessary staging tests performed prior to R-CHOPor steroids including CT and/or PET/CTscans, and bone marrow biopsy. Treatment must occur within 30 days prior to enrollment.
- No prior therapy with PI3K inhibitors or Bruton tyrosine kinase (BTK) inhibitors
- ECOG Performance status ≤2. Performance Status of 3 will be accepted if impairment is caused by DLBCL complications and improvement is expected once therapy is initiated.
Participants must have adequate hematologic, hepatic, and renal function as defined below:
- Hemoglobin ≥9.0g/dl unless the anemia is clearly due to DLBCL. If there is BM involvement, this criteria can be waived after discussion with the Sponsor Investigator (per investigators discretion).
- Absolute neutrophil count≥1,000/mcL, unless the neutropenia is clearly due to DLBCL. If there is BM involvement, this criteria can be waived after discussion with the Sponsor Investigator(per investigator discretion)
- Platelet count ≥75,000/mcl unless thrombocytopenia is clearly due to DLBCL. If there is BM involvement, this criteria can be waived after discussion with the Sponsor Investigator(per investigator discretion)
- Bilirubin ≤ 2.0 x ULN unless considered secondary to Gilbert's syndrome, in which case ≤ 3 x ULN
- AST (SGOT) < 2.0 x institutional upper limit of normal
- ALT (SGPT) < 2.0 x institutional upper limit of normal
- Creatinine clearance ≥45 mL/min calculated by Cockcroft-Gault or 24 hour collection
- Adequate cardiac function left ventricular ejection fraction (LVEF) ≥50% as assessed by echocardiogram or MUGA (Multi Gated Acquisition Scan).
- QT-interval corrected according to Fridericia's formula (QTcF) ≤450 milliseconds (ms); participants with QTc < 480 msec may be enrolled provided the QTc prolongation is due to a right bundle branch block and stable .
- Negative pregnancy test in women of child-bearing age. The effects of ME-401 on the developing human fetus are unknown. For this reason and because chemotherapeutic agents used in this study are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (double barrier method of birth control or abstinence) 2 weeks prior to initiation of treatment, for the duration of study participation and for 3 months after completing treatment. Should a woman become pregnant or suspect that she is pregnant while she or her partner is participating in this study, she should inform the treating physician immediately. Men must agree to refrain from sperm donation for at least 90 days after the last dose of ME-401
- Participants must have the ability to understand and the willingness to sign a written informed consent document.
International Prognostic Index must be documented:
- ECOG performance status ≥2
- Age ≥60 years
- extranodal sites ≥ 2
- LDH >upper limit of normal
- Ann Arbor Stage III or IV
- Is there evidence of transformation from indolent lymphoma?
Exclusion Criteria:
- Participants receiving any other investigational agents.
- Known CNS involvement by lymphoma. Participants at high risk for secondary CNS involvement but without neurologic symptoms suspected to be due to lymphoma are allowed to be enrolled and receive prophylactic intrathecal chemotherapy including but not limited to methotrexate, cytarabine and glucocorticoids. Participants who are enrolled and subsequently identified to have pathologic confirmation of CNS involvement by lymphoma may be continued on study at the discretion of the principal investigator.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to R-CHOP.
- Participants with ongoing uncontrolled illness including, but not limited to ongoing significantly active infections requiring intravenous antibiotics, hypertension, angina, arrhythmias, pulmonary disease, or autoimmune dysfunction.
- Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia.
- Ongoing drug-induced pneumonitis.
History of clinically significant gastrointestinal (GI) conditions, particularly:
- Known GI condition that would interfere with swallowing or the oral absorption or tolerance of study drug
- Pre-existing malabsorption syndrome or other clinical situation that would
- Active congestive heart failure (New York Heart Association [NYHA] Class>2), symptomatic ischemia, or conduction abnormalities uncontrolled by conventional intervention or myocardial infarction within six months prior to enrollment.
- Participants who have tested positive for hepatitis B surface antigen and/or hepatitis B core antibody PLUS have detectable viral load on hepatitis B polymerase chain reaction (PCR) assay (participants with a negative PCR assay are permitted with appropriate anti-viral prophylaxis)
- Positive hepatitis C virus antibody (HCV Ab) participants with positive hepatitis C antibody are eligible if they are negative for hepatitis C virus by PCR
- HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ME-401
- Pregnant or breastfeeding women are excluded from this study because there are no studies assessing the reproductive and developmental toxicity or excretion into breast milk of ME-401. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with ME-401, breastfeeding should be discontinued if the mother is treated with ME-401. These potential risks may also apply to other drugs used in this study.
- Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin, or low-risk prostate cancer after curative therapy.
- Participants who have had major surgical procedures or significant traumatic injury within 28 days prior to study treatment.
- Psychiatric illness/social situations that would interfere with study compliance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ME-401 + R-CHOP
Participants will receive ME-401 dose dependent on dose-escalation schedule at time of enrollment - all will receive standard dose R-CHOP.
ME-401 (60 mg) will be given on days 1-4 (dose level 1) OR days 1-7 (dose level 2) of a 21 day cycle with standard dose R-CHOP x 6 cycles.
|
ME-401 (60 mg) will be given by mouth every 21 days for 6 cycles on days 1-4 (dose level 1) OR days 1-7 (dose level 2) of a 21 day cycle.
Dose escalation will be performed in a standard 3+3 design
Other Names:
375 mg/m2 IV/subcutaneous rituximab day 1 of 21-day cycle. First dose of rituximab will be given IV and subsequent doses can be either IV or SQ based on institutional guidelines.
Other Names:
750 mg/m2 IV Cyclophosphamide day 1 of 21-day cycle
Other Names:
50 mg/m2 IV Doxorubicin day 1 of 21-day cycle
Other Names:
1.4 mg/m2 (max 2 mg) IV Vincristine
Other Names:
100mg PO Prednisone Days 1-5 of 21-day cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of clinically significant non-hematologic grade 3 or 4 treatment-related AEs or hematologic grade 3 or 4 treatment related AEs
Time Frame: Up to 24 months after treatment
|
Dose limiting toxicity (DLT) as defined by non-hematologic clinically significant grade 3 or 4 treatment-related AEs or hematologic grade 3 or 4 treatment related AEs that are clinically significant during the first cycle, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0.
|
Up to 24 months after treatment
|
Progression free survival (PFS) assessed by Lugano criteria
Time Frame: 36 months (3 years) after completion of therapy or until death, whichever comes first
|
PFS, as defined as time from study treatment initiation to documented disease progression per Lugano Criteria, or death from any cause, whichever occurs first.
|
36 months (3 years) after completion of therapy or until death, whichever comes first
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of treatment-related AEs in Phase I
Time Frame: Up to 24 months after treatment
|
Number of treatment-related AEs in Phase I. Participants will be followed for toxicity for 30 days after treatment has been discontinued or until death, whichever occurs first. The clinical course of each event will be followed until resolution, stabilization, or until it has been determined that the study treatment or participation is not the cause with a cut off of 24 months after completion of therapy. |
Up to 24 months after treatment
|
Number of treatment-related AEs in Phase II
Time Frame: Up to 24 months after treatment
|
Number of treatment-related AEs in Phase II Participants will be followed for toxicity for 30 days after treatment has been discontinued or until death, whichever occurs first. The clinical course of each event will be followed until resolution, stabilization, or until it has been determined that the study treatment or participation is not the cause with a cut off of 24 months after completion of therapy. |
Up to 24 months after treatment
|
Number of days treatment is delayed
Time Frame: Up to 24 months after treatment
|
Number of days treatment is delayed
|
Up to 24 months after treatment
|
Overall Response (OR) assessed by Lugano criteria
Time Frame: 36 months (3 years) after completion of therapy or until death, whichever comes first
|
OR assessed by Lugano criteria.
OR is defined as achieving either CR or PR at any stage from time of commencement of protocol treatment to time of treatment cessation for whatever reason
|
36 months (3 years) after completion of therapy or until death, whichever comes first
|
Complete Response (CR) assessed by Lugano criteria
Time Frame: 36 months (3 years) after completion of therapy or until death, whichever comes first
|
CR assessed by Lugano criteria
|
36 months (3 years) after completion of therapy or until death, whichever comes first
|
Partial Response (PR) assessed by Lugano criteria
Time Frame: 36 months (3 years) after completion of therapy or until death, whichever comes first
|
PR assessed by Lugano criteria
|
36 months (3 years) after completion of therapy or until death, whichever comes first
|
Duration of Response (DoR)
Time Frame: 36 months (3 years) after completion of therapy or until death, whichever comes first
|
DoR defined as the time from documented response (CR or PR) to the time of confirmed disease progression or death due to any cause, whichever occurs first
|
36 months (3 years) after completion of therapy or until death, whichever comes first
|
Overall Survival (OS)
Time Frame: 36 months (3 years) after completion of therapy or until death, whichever comes first
|
OS defined as the time from first dose of study treatment to death from any cause
|
36 months (3 years) after completion of therapy or until death, whichever comes first
|
Time to Treatment Failure
Time Frame: 36 months (3 years) after completion of therapy or until death, whichever comes first
|
Time to Treatment Failure defined as the time from study entry to any treatment failure.
|
36 months (3 years) after completion of therapy or until death, whichever comes first
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Deepa Jagadeesh, MD, MPH, Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antineoplastic Agents, Immunological
- Antibiotics, Antineoplastic
- Cyclophosphamide
- Rituximab
- Prednisone
- Doxorubicin
- Liposomal doxorubicin
- Vincristine
Other Study ID Numbers
- CASE1420
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diffuse Large B-Cell Lymphoma
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell LymphomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); AmgenActive, not recruitingRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | CD20 Positive | Stage I Diffuse Large B-Cell Lymphoma | Stage II Diffuse Large B-Cell Lymphoma | Stage III Diffuse Large B-Cell Lymphoma | Stage IV Diffuse Large B-Cell LymphomaUnited States
-
University Hospital Southampton NHS Foundation...Hoffmann-La RocheTerminatedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited Kingdom
-
National Cancer Institute (NCI)WithdrawnDiffuse, Large B-cell Lymphoma | Lymphoma, Diffuse Large-Cell | Lymphoma, Diffuse Large-Cell B-cell | Large-Cell Lymphoma, Diffuse
-
Qian WenbinNot yet recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaChina
-
Dana-Farber Cancer InstituteBayer; AbbVieActive, not recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterSanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaboratorsActive, not recruitingDiffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)United States
-
Autolus LimitedCompletedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | DLBCL | Relapsed Diffuse Large B-Cell LymphomaUnited States, United Kingdom
-
Herlev HospitalOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsCompletedDiffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Cell of Origin
-
UNC Lineberger Comprehensive Cancer CenterCephalonCompletedLymphoma | Diffuse Large B-Cell Lymphoma | Lymphoma, Diffuse Large-Cell | Diffuse Large-Cell LymphomaUnited States
Clinical Trials on ME-401
-
Kyowa Kirin Co., Ltd.Active, not recruitingStudy of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)Indolent B-cell Non-Hodgkin's LymphomaJapan
-
Kyowa Kirin Co., Ltd.Active, not recruitingRelapsed or Refractory Indolent B-cell Non-Hodgkin's LymphomaJapan
-
MEI Pharma, Inc.TerminatedMarginal Zone Lymphoma | Non Hodgkin Lymphoma | Follicular Lymphoma (FL)United States, Spain, Korea, Republic of, Belgium, Taiwan, Germany, France, Italy, Australia, Poland, New Zealand, United Kingdom, Austria, Switzerland
-
Jacob Soumerai, MDMEI Pharma, Inc.WithdrawnRelapsed Follicular Lymphoma | Refractory Follicular LymphomaUnited States
-
Eugene Lee, MDUniversity of Kansas Medical CenterCompletedBladder CancerUnited States
-
Neurogene Inc.RecruitingRett SyndromeUnited States
-
MEI Pharma, Inc.Kyowa Kirin, Inc.Withdrawn
-
Forte Biosciences, Inc.Terminated
-
Benitec BioPharma LtdCompletedHead and Neck Squamous Cell CarcinomaAustralia, Russian Federation
-
Celgene CorporationTerminatedMyeloid LeukemiaUnited States